Longeveron Inc.
LGVN$12M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaMIAMI
Drugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
LGVN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Lomecel-B medicinal signaling cells
Hypoplastic Left Heart Syndrome
Fluzone High Dose Vaccine
Aging Frailty
Allogeneic MSC
Mild Alzheimer's Disease
Longeveron Mesenchymal Stem Cells (LMSCs)
Aging Frailty
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Frailty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lomecel-B medicinal signaling cells | Phase 2 | Hypoplastic Left Heart Syndrome | - | - |
Fluzone High Dose Vaccine | Phase 2 | Aging Frailty | - | - |
Allogeneic MSC | Phase 2 | Mild Alzheimer's Disease | - | - |
Longeveron Mesenchymal Stem Cells (LMSCs) | Phase 2 | Aging Frailty | - | - |
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Phase 2 | Frailty | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply